# Nausea Medicine Market

> Global Nausea Medicine Market Research Report Information By Type (Antagonists, Antihistamines, Cannabinoids and Others), By Mode of Administration (Intravenous, Oral and Transdermal), Indication (Oncology, Gastroesophageal Reflux Disease (GERD), Motion Sickness and Seasickness and Others), Distribution Channel (Hospitals Pharmacy/ Retail Pharmacy and Online), Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.98%
- **2024:** $ 3.66 Billion
- **2025:** $ 3.92 Billion
- **2035:** $ 7.69 Billion
- **Key Players:** Bristol-Myers Squibb (US), GlaxoSmithKline (GB), Merck & Co. (US), Pfizer (US), Sanofi (FR), Teva Pharmaceutical Industries (IL), AstraZeneca (GB), Novartis (CH)

**Report ID:** MRFR/Pharma/3105-CR · **Pages:** 104 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** March 26, 2026

**URL:** https://www.marketresearchfuture.com/reports/nausea-medicine-market-4523

---

## Market Summary

## **Global Nausea Medicine Market Overview **

Nausea Medicine Market Size was valued at USD 3.42 Billion in 2023. The Global Nausea Medicine industry is projected to grow from USD 3.66 Billion in 2024 to USD 6.24 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.20% during the forecast period (2024 - 2032).

Nausea medicines are those that have the ability to treat conditions such as nausea and vomiting. The growing cases of cancer rise in gastrointestinal diseases, and increasing geriatric population, sedentary lifestyle and unhealthy diet, are driving the global nausea medicine market. However, a high preference for home remedies is expected to hamper the growth of this market during the forecast period. Nevertheless, collaborations between large drug manufacturing companies and small companies are likely to set a lucrative opportunity for the growth of this market in the near future.

## **Nausea Medicine Market Dynamics**

Cancer has a major impact on society in the United States and across the world. According to the National Cancer Institute, in 2020, roughly 1.8 Million people will be diagnosed with cancer in the United States. An estimated 276,480 women and 2,620 men will be diagnosed with breast cancer, which makes it the most common cancer diagnosis. According to Cancer Research UK, in females in the UK, there were more than 179,000 new cancer cases in 2017, and in males in the UK, there were around 187,000 new cancer cases in 2017.

Such a rising number of people being affected by different types of cancer is driving the growth of the nausea medicine market. Chemotherapy is one of the standard treatments used to deal with cancer and is also accompanied by side effects of nausea and vomiting. Chemotherapy-induced vomiting and early stage of pregnancy require nausea medicine throughout the therapy. Thus, nausea medicine would witness an increase in sales due to growing cases of cancer during the forecast period.

## **Nausea Medicine Market Segment Insights**

Global Nausea Medicine Market has been segmented By Type, Mode of Administration, Indication, and Distribution Channel.

### **Nausea Medicine Type Insights**

The nausea medicine market, on the basis of type, has been segmented into antagonists, cannabinoids, antihistamines, and others. 

### **Nausea Medicine Mode of Administation Insights**

The nausea medicine market, based on the mode of administration, is divided into oral, intravenous, and others. The nausea medicine market, based on indication, is divided into oncology, gastroesophageal reflux disease (GERD), motion sickness, and others. The nausea medicine market, based on distribution channel, is divided into hospital/retail pharmacies and online.

By indication, the oncology segment held the largest share of 39.84% in 2019 owing to an increasing number of patients experiencing nausea associated with chemotherapeutic drug use.

### **Nausea Medicine Regional Insights**

Global Nausea Medicine Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is likely to dominate the global nausea medicine market. This large share can be attributed to the presence of major manufacturers, rising awareness about early disease diagnosis, and the rising prevalence of gastrointestinal diseases.    

The European market is the second-largest market for nausea medicine. Factors such as a boost in the biopharmaceutical sector in the European region, improving economies, high disposable income per individual, and increased healthcare spending are driving the growth of the market in this region.  

The market in Asia-Pacific is expected to register a significant growth rate during the forecast period owing to growing awareness about diseases, government support to improve the healthcare sector, and rising geriatric population.

The nausea medicine market in the Middle East & Africa is projected to show gradual growth during the forecast period. In this region, the Middle East is anticipated to dominate owing to the number of cancer populations and high incidences of gastroenteritis and other gastrointestinal diseases.

## **Nausea Medicine Market Key Players**

The Prominent Players in the Global Nausea Medicine Market are

Some of the key strategies followed by players operating in the global market were innovation, product development, expansion, and acquisition & mergers.

## **Nausea Medicine Market Segmentation**

### ** Nausea Medicine****Type Outlook**

### **Nausea Medicine****Mode of Administration Outlook**

### ** Nausea Medicine Indication Outlook**

### **Nausea Medicine Distribution Channel Outlook**

### **Nausea Medicine Region Outlook**

**Available Additional Customizations**

**Intended Audience**

## Market Drivers

### Expansion of E-commerce Platforms

The expansion of e-commerce platforms is transforming the way consumers access nausea medications, thereby impacting the Nausea Medicine Market. With the rise of online pharmacies and health-focused e-commerce sites, consumers now have greater access to a variety of nausea relief products. This trend is particularly relevant in regions where traditional pharmacies may be limited. The convenience of online shopping, coupled with the ability to compare prices and read reviews, is likely to drive sales in the nausea medicine sector. As e-commerce continues to grow, it may contribute to a significant increase in market penetration for nausea medications.

### Rising Awareness of Nausea Management

There is a growing awareness regarding the importance of effective nausea management among healthcare professionals and patients alike, which is likely to propel the Nausea Medicine Market. Educational initiatives and campaigns aimed at informing the public about the various causes and treatments for nausea have contributed to this trend. As patients become more informed about their options, they are more inclined to seek medical advice and appropriate treatments. This increased awareness may lead to a higher demand for both prescription and over-the-counter nausea medications, thereby expanding the market further.

### Advancements in Pharmaceutical Research

Recent advancements in pharmaceutical research and development are significantly influencing the Nausea Medicine Market. The introduction of novel drug formulations and delivery systems, such as transdermal patches and sublingual tablets, has enhanced the efficacy and convenience of nausea treatments. Furthermore, the market has witnessed a surge in clinical trials aimed at discovering new antiemetic agents, which could potentially offer improved outcomes for patients. As a result, the industry is expected to experience growth driven by these innovations, with a projected increase in market value reaching several billion dollars in the coming years.

### Increased Focus on Preventive Healthcare

The increasing focus on preventive healthcare is emerging as a notable driver for the Nausea Medicine Market. As healthcare systems worldwide shift towards preventive measures, there is a growing emphasis on managing symptoms before they escalate into more severe conditions. This proactive approach encourages individuals to seek out nausea medications as a means of prevention, particularly in high-risk populations such as pregnant women and patients undergoing certain medical treatments. Consequently, this trend may lead to a sustained increase in demand for nausea medicines, as healthcare providers advocate for early intervention strategies.

### Growing Incidence of Nausea-Related Conditions

The rising prevalence of nausea-related conditions, such as motion sickness, [chemotherapy](https://www.marketresearchfuture.com/reports/chemotherapy-market-5791)-induced nausea, and pregnancy-related nausea, appears to be a primary driver for the Nausea Medicine Market. According to recent estimates, approximately 30% of the population experiences motion sickness at some point in their lives. Additionally, the increasing number of cancer patients undergoing chemotherapy has led to a heightened demand for effective antiemetic medications. This trend suggests that as more individuals seek relief from nausea, the market for nausea medicines will likely expand, with pharmaceutical companies focusing on developing innovative solutions to address these conditions.

## Future Outlook

The Nausea Medicine Market is projected to grow at a 6.98% CAGR from 2025 to 2035, driven by increasing healthcare access, rising awareness, and innovative drug development.

**New opportunities:**

- Expansion of telehealth services for nausea management
- Development of personalized medicine targeting specific nausea causes
- Investment in biodegradable drug delivery systems for enhanced patient compliance

By 2035, the Nausea Medicine Market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Antihistamines (Largest) vs. Cannabinoids (Fastest-Growing)

In the Nausea Medicine Market, the segment distribution reveals that Antihistamines hold the largest market share, being the most commonly utilized for treating nausea across various demographics. Their established efficacy and familiar presence in the market contribute to their dominance. Conversely, Cannabinoids are quickly emerging as a noteworthy alternative, appealing particularly to patients seeking more natural options for nausea relief, influenced by changing regulations and attitudes toward cannabis products.

Antihistamines (Dominant) vs. Cannabinoids (Emerging)

Antihistamines have well-established efficacy in managing nausea, particularly related to motion sickness, allergies, and post-operative situations, solidifying their position as the dominant player in the nausea medicine segment. They benefit from a broad range of available products, including both prescription and over-the-counter options, which cater to different patient needs. Meanwhile, Cannabinoids are rapidly gaining traction as an emerging segment, especially with the proliferation of cannabis products and growing research supporting their therapeutic potential for chemotherapy-induced nausea and chronic pain management. This segment's rapid growth is attributed to increasing acceptance and legalization in various regions, appealing to a demographic searching for holistic and alternative treatments.

### By Mode of Administration: Intravenous (Largest) vs. Oral (Fastest-Growing)

In the Nausea Medicine Market, the mode of administration plays a pivotal role in defining consumer preferences and therapeutic outcomes. Intravenous administration currently holds the largest market share, as it provides rapid relief and is preferred in acute settings. On the other hand, oral administration is emerging strongly due to its convenience and patient compliance, appealing particularly to chronic nausea management. Despite being the largest, the intravenous segment faces competition from the faster-growing oral segment, which is increasingly gaining traction among healthcare providers and patients alike.

The growth trends in the mode of administration segment are driven by an increase in outpatient procedures and the demand for [home healthcare](https://www.marketresearchfuture.com/reports/home-healthcare-market-2030) solutions. As more patients look for accessible and manageable options for nausea treatment, oral administration is becoming the preferred choice, leading to its rapid growth. Innovations in formulations and delivery methods are also enabling new oral therapies to enter the market, further fueling this upward trajectory. Furthermore, awareness around nausea management and treatment options is contributing to the overall expansion of both segments, with intravenous administration remaining critical in acute care scenarios.

Intravenous (Dominant) vs. Oral (Emerging)

The intravenous mode of administration represents the dominant player in the Nausea Medicine Market, primarily utilized in hospital settings for immediate nausea relief, making it essential for acute treatment scenarios, such as chemotherapy or postoperative care. Its ability to deliver medication directly into the bloodstream ensures quick action, thus catering effectively to patients requiring prompt management of severe nausea. Conversely, the oral mode of administration is categorized as an emerging option, gaining popularity for its ease of use and suitability for outpatient care. Many patients prefer oral medications for chronic conditions due to their less invasive nature and simplicity in self-administration, which fosters better adherence to treatment regimens. This growing preference for oral solutions reflects changing patient needs and influences the ongoing evolution of the nausea treatment landscape.

### By Indication: Oncology (Largest) vs. Motion Sickness And Seasickness (Fastest-Growing)

In the Nausea Medicine Market, the 'Indication' segment is primarily dominated by Oncology, which holds the largest share due to the increasing prevalence of cancer and the associated need for effective nausea management during chemotherapy. Gastroesophageal Reflux Disease (GERD) follows as a significant contributor, as rising awareness and diagnosis drive demand for medications to manage nausea linked to this condition. Motion Sickness and Seasickness represent a smaller but increasingly important segment, with more consumers seeking out remedies as travel and recreational activities resume post-pandemic.

Oncology (Dominant) vs. Motion Sickness And Seasickness (Emerging)

The oncology segment is a powerhouse in the Nausea Medicine Market, fueled by the rising incidences of cancer diagnoses and the consequent increase in chemotherapy treatments that induce nausea. This segment continues to benefit from advancements in drug formulation and delivery methods, catering to the specific needs of patients undergoing treatment. In contrast, the motion sickness and seasickness segment is emerging robustly, driven by increasing consumer awareness and the growth of travel and outdoor activities. Innovative formulations targeting quick relief are appealing to these consumers, making this segment the fastest-growing, despite its smaller overall market share.

### By Distribution Channel: Pharmacy (Largest) vs. Online (Fastest-Growing)

In the Nausea Medicine Market, distribution channels play a critical role in reaching consumers effectively. Hospitals Pharmacy holds the largest market share, serving as a key point for patients seeking immediate relief from nausea, particularly in acute care settings. Retail pharmacies also contribute significantly to this segment, providing access to over-the-counter options. Online distribution, while currently a smaller part of the overall market, is rapidly gaining traction as more consumers prefer the convenience of purchasing medications from home.

Pharmacy (Dominant) vs. Online (Emerging)

The Pharmacy segment remains dominant in the Nausea Medicine Market, driven by established relationships with healthcare providers and a strong physical presence that facilitates patient access to medications. Hospitals and retail pharmacies offer a comprehensive range of products, including prescription and over-the-counter nausea medications, ensuring immediate availability for patients. Conversely, the Online channel is emerging as a fast-growing alternative, appealing particularly to tech-savvy consumers and those seeking discreet purchase options. The convenience of home delivery and the ability to compare prices online are significant growth drivers for this segment, attracting a younger demographic that values accessibility.

## Regional Market Share Analysis

### North America : Market Leader in Nausea Treatment

North America is the largest market for nausea medicine, holding approximately 45% of the global share. The region's growth is driven by increasing incidences of nausea-related conditions, such as motion sickness and chemotherapy-induced nausea. Regulatory support from agencies like the FDA has also catalyzed the introduction of innovative therapies, enhancing market dynamics. The rising awareness of nausea management among healthcare providers further fuels demand.

The United States is the primary contributor to this market, with significant participation from Canada. Key players like Bristol-Myers Squibb, Merck & Co., and Pfizer dominate the landscape, offering a range of effective treatments. The competitive environment is characterized by ongoing research and development, with companies focusing on novel formulations and delivery methods to meet patient needs. This competitive edge is crucial for maintaining market leadership.

### Europe : Emerging Market with Growth Potential

Europe is witnessing a growing demand for nausea medicine, accounting for approximately 30% of the global market share. Factors such as an aging population, increased prevalence of chronic diseases, and a rise in surgical procedures contribute to this growth. Regulatory frameworks across the EU are becoming more supportive, facilitating quicker approvals for new treatments. The emphasis on patient-centered care is also driving the demand for effective nausea management solutions.

Leading countries in this region include Germany, France, and the UK, where healthcare systems are increasingly prioritizing nausea treatment. Major players like GlaxoSmithKline and Sanofi are actively involved in this market, focusing on innovative therapies and strategic partnerships. The competitive landscape is marked by a mix of established pharmaceutical companies and emerging biotech firms, all striving to capture market share through advanced research and development initiatives.

### Asia-Pacific : Rapidly Growing Healthcare Sector

Asia-Pacific is emerging as a significant player in the nausea medicine market, holding around 20% of the global share. The region's growth is propelled by increasing healthcare expenditure, rising awareness of nausea management, and a growing population. Countries like India and China are witnessing a surge in demand due to lifestyle changes and increased incidences of nausea-related conditions. Regulatory bodies are also enhancing their frameworks to support the introduction of new therapies, further stimulating market growth.

China and India are the leading countries in this region, with a burgeoning pharmaceutical sector that attracts both local and international players. Companies like Teva Pharmaceutical Industries and AstraZeneca are expanding their presence, focusing on innovative solutions tailored to regional needs. The competitive landscape is characterized by a mix of multinational corporations and local firms, all vying for a share of this rapidly growing market.

### Middle East and Africa : Untapped Market with Opportunities

The Middle East and Africa represent an untapped market for nausea medicine, holding approximately 5% of the global share. The region's growth is driven by increasing healthcare investments, rising awareness of health issues, and a growing population. Regulatory bodies are beginning to implement frameworks that support the introduction of new medications, which is crucial for market expansion. The demand for effective nausea treatments is expected to rise as healthcare access improves across various countries.

Leading countries in this region include South Africa and the UAE, where healthcare systems are evolving to meet patient needs. The competitive landscape is still developing, with opportunities for both local and international players to enter the market. Companies are focusing on establishing partnerships and collaborations to enhance their product offerings and reach a broader audience, paving the way for future growth.

## Competitive Benchmarking

The Nausea Medicine Market is characterized by a dynamic competitive landscape, driven by increasing demand for effective treatments across various indications, including chemotherapy-induced nausea and motion sickness. Key players such as Bristol-Myers Squibb (US), GlaxoSmithKline (GB), and Merck & Co. (US) are strategically positioned to leverage their extensive research and development capabilities. Bristol-Myers Squibb (US) focuses on innovation through the development of novel therapies, while GlaxoSmithKline (GB) emphasizes partnerships to enhance its product portfolio. Merck & Co. (US) is actively pursuing regional expansion, particularly in emerging markets, which collectively shapes a competitive environment that is both collaborative and aggressive in nature.

The market structure appears moderately fragmented, with several players vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which is essential in maintaining competitive pricing. The influence of major companies is significant, as their strategic initiatives often set industry standards and drive market trends, thereby impacting smaller players and new entrants.

In August 2025, GlaxoSmithKline (GB) announced a strategic partnership with a leading biotechnology firm to co-develop a new nausea treatment aimed at patients undergoing cancer therapy. This collaboration is expected to enhance GSK's research capabilities and expedite the development process, reflecting a broader trend of companies seeking synergies to innovate more rapidly in response to patient needs. The partnership underscores the importance of collaboration in a market where speed to market can be a critical differentiator.

In September 2025, Merck & Co. (US) launched a new digital health initiative aimed at improving patient adherence to nausea medications through a mobile application. This initiative not only enhances patient engagement but also positions Merck as a leader in integrating technology with traditional pharmaceutical offerings. The move indicates a shift towards digital solutions that can complement pharmacological treatments, potentially improving outcomes and patient satisfaction.

In July 2025, Sanofi (FR) expanded its manufacturing capabilities in Asia to meet the growing demand for its nausea medications. This expansion is strategically significant as it allows Sanofi to enhance its supply chain efficiency and respond more effectively to regional market needs. The investment reflects a broader trend of companies optimizing their operations to ensure reliability and responsiveness in a competitive market.

As of October 2025, current trends in the Nausea Medicine Market include a pronounced focus on digitalization, sustainability, and the integration of artificial intelligence in drug development and patient management. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and the reliability of supply chains, as companies strive to meet the complex needs of patients and healthcare providers.

## Report Scope

| MARKET SIZE 2024 | 3.66(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 3.915(USD Billion) |
| MARKET SIZE 2035 | 7.688(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.98% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Bristol-Myers Squibb (US), GlaxoSmithKline (GB), Merck & Co. (US), Pfizer (US), Sanofi (FR), Teva Pharmaceutical Industries (IL), AstraZeneca (GB), Novartis (CH) |
| Segments Covered | Type, Mode of Administration |
| Key Market Opportunities | Emergence of personalized medicine and digital therapeutics in the Nausea Medicine Market. |
| Key Market Dynamics | Rising consumer demand for effective nausea treatments drives innovation and competition among pharmaceutical companies. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Nausea Medicine Market?**
A: As of 2024, the Nausea Medicine Market was valued at 3.66 USD Billion.

**Q: What is the projected market size for the Nausea Medicine Market in 2035?**
A: The market is projected to reach 7.688 USD Billion by 2035.

**Q: What is the expected CAGR for the Nausea Medicine Market from 2025 to 2035?**
A: The expected CAGR for the Nausea Medicine Market during the forecast period 2025 - 2035 is 6.98%.

**Q: Which companies are the key players in the Nausea Medicine Market?**
A: Key players include Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co., Pfizer, Sanofi, Teva Pharmaceutical Industries, AstraZeneca, and Novartis.

**Q: What are the main types of nausea medicines and their market valuations?**
A: In 2024, Antihistamines were valued at 1.1 USD Billion, while Antagonists and Cannabinoids were valued at 0.73 USD Billion and 0.55 USD Billion, respectively.

**Q: How does the mode of administration affect the Nausea Medicine Market?**
A: In 2024, the Oral administration segment was valued at 1.83 USD Billion, indicating a strong preference for this mode.

**Q: What indications drive the demand for nausea medicines?**
A: The Oncology indication was valued at 0.8 USD Billion in 2024, while Gastroesophageal Reflux Disease (GERD) reached 1.2 USD Billion.

**Q: What distribution channels are prevalent in the Nausea Medicine Market?**
A: In 2024, Hospitals Pharmacy/Retail Pharmacy accounted for 2.2 USD Billion, highlighting its dominance in distribution.

**Q: What is the growth potential for cannabinoids in the Nausea Medicine Market?**
A: The Cannabinoids segment is projected to grow from 0.55 USD Billion in 2024 to 1.2 USD Billion by 2035.

**Q: How does the market for nausea medicines compare across different segments?**
A: The Antihistamines segment is expected to grow significantly, from 1.1 USD Billion in 2024 to 2.3 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/nausea-medicine-market-4523*